BPA / BPS / BPF (bisphenols)
Toxins · Endocrine disruptor
Moderate priority
What this is
EFSA 2023 TDI reduction of 20,000-fold is one of the most dramatic regulatory changes in chemical risk assessment. FDA largely disagrees with EFSA's assessment. BPS/BPF replacements show similar endocrine activity in vitro — don't assume 'BPA-free' = 'safe'. Thermal receipts deliver detectable BPA through skin.
Mechanism
Bisphenol A (polycarbonate plastics, epoxy can linings, thermal paper receipts); weak estrogen receptor agonist; 'BPA-free' often means BPS/BPF — structurally similar, likely similar concerns ('regrettable substitution')
Dose & route
Glass/stainless; BPA-free cans (Eden, Muir Glen, some Amy's); don't microwave plastics; limit thermal receipt handling
Citations
- https://pubmed.ncbi.nlm.nih.gov/37112910/
- https://pubmed.ncbi.nlm.nih.gov/26001964/
- https://pmc.ncbi.nlm.nih.gov/articles/PMC7103598/
Links go to the source. If a link is dead or you want something re-checked, let me know.
This is an independent synthesis of published research by a non-clinician. Scores are opinions supported by citations, not prescriptions. See the full disclaimer and methodology for how this score was produced and what it does and doesn't mean.